Knowledge, Perspectives, and Experiences of Women in Kuwait Regarding GLP-1/GIP–Based Medications for Weight Management: A Cross-Sectional Study
Authors:
- Maha AlharbiMAMaha Alharbi
- Malak AlshammariMAMalak Alshammari
- Afrah AlkazemiAAAfrah Alkazemi
- 9 November 2026
- journal article
- Published by Elsevier in Clinical Therapeutics
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Obesity rise plateaus in developed nations and accelerates in developing nationsNature, 2026
- An experimental investigation of the stigmatization of weight loss and regain from GLP-1 receptor agonist use and cessationInternational Journal of Obesity, 2026
- Assessment of community awareness and attitude about the use of GLP 1 agonists as a treatment for obesity in Saudi Arabia: Cross-sectional studyMedicine, 2026
- American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease – 2025 UpdateEndocrine Practice, 2025
- What are community perspectives and experiences around GLP-1 receptor agonist medications for weight loss? A cross-sectional survey study in the UKBMJ Public Health, 2025
- Definition and diagnostic criteria of clinical obesityThe Lancet Diabetes & Endocrinology, 2025
- The effect of GLP-1 receptor agonist use on negative evaluations of women with higher and lower body weightInternational Journal of Obesity, 2024
- Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adultsThe Lancet, 2024
- Public Interest in the Off-Label Use of Glucagon-like Peptide 1 Agonists (Ozempic) for Cosmetic Weight Loss: A Google Trends AnalysisAesthetic Surgery Journal, 2023
- Changes in weight bias following weight loss: the impact of weight-loss methodInternational Journal of Obesity, 2011